DNA persistence after treatment of Lyme borreliosis
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- Borrelia burgdorferi komplex genetika MeSH
- časové faktory MeSH
- DNA bakterií izolace a purifikace MeSH
- lidé MeSH
- lymeská nemoc farmakoterapie mikrobiologie MeSH
- polymerázová řetězová reakce MeSH
- tělesné tekutiny mikrobiologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- DNA bakterií MeSH
One hundred twenty-four patients-53 with neuroborreliosis, 48 with erythema migrans, and 23 with Lyme arthritis-were tested in a prospective study for the presence of the DNA of Borrelia burgdorferi sensu lato in plasma, cerebrospinal fluid (CSF), urine, and synovial fluid by nested polymerase chain reaction (PCR). Specific DNA was detected using five amplification systems simultaneously: three targeted chromosomal genes encoding 16S rDNA, flagellin, and p66; and two plasmid sequences of OspA and OspC. Patients were examined clinically and by PCR before and after treatment and again after 3 and 6 months. Before treatment, the specific DNA was detected in 78 patients (62.9 %). Forty-one neuroborreliosis patients were DNA-positive (77.4 %), with CSF positivity in 26 patients, urine in 25, and plasma in 16. Twenty-six erythema migrans patients were DNA-positive (54.2 %), with plasma positivity in 18 cases and urine in 14. Eleven Lyme arthritis cases (47.8 %) were DNA positive (six in urine, five in plasma, and four in synovial fluid). The frequency of PCR positives was comparable in CSF and urine, and it was lower by approximately 50 % in plasma. Specific DNA was also found in a significant number of patients in later testing periods: 48 patients after treatment, 29 patients after 3 months, and 6 patients after 6 months. The prolonged PCR positivity was not explainable by persistent infection according to the clinical manifestations of the disease. Possible explanations of the problem are discussed.
Zobrazit více v PubMed
N Engl J Med. 2007 Oct 4;357(14):1422-30 PubMed
Arthritis Rheum. 2006 Oct;54(10):3079-86 PubMed
Ann Rheum Dis. 1998 Feb;57(2):118-21 PubMed
J Womens Health (Larchmt). 2009 Jun;18(6):831-4 PubMed
Eur J Neurol. 2010 Jan;17(1):8-16, e1-4 PubMed
Acta Neurol Scand. 2005 Nov;112(5):287-92 PubMed
Clin Rheumatol. 2012 Jun;31(6):989-94 PubMed
Antimicrob Agents Chemother. 2008 May;52(5):1728-36 PubMed
PLoS One. 2012;7(1):e29914 PubMed
Zentralbl Bakteriol. 1999 Jul;289(3):301-18 PubMed
Lancet. 2012 Feb 4;379(9814):461-73 PubMed
J Clin Microbiol. 2013 Mar;51(3):857-62 PubMed
APMIS Suppl. 2002;(105):1-40 PubMed
Clin Diagn Lab Immunol. 2005 Aug;12(8):910-7 PubMed
N Engl J Med. 1994 Jan 27;330(4):229-34 PubMed
Clin Infect Dis. 2006 Nov 1;43(9):1089-134 PubMed
Clin Lab Med. 2003 Dec;23(4):867-84, vi PubMed
J Am Acad Dermatol. 2011 Apr;64(4):639-53; quiz 654, 653 PubMed
J Clin Microbiol. 2002 Dec;40(12):4581-4 PubMed
J Neurol Sci. 1993 Aug;118(1):64-72 PubMed
Clin Infect Dis. 2007 Jul 15;45(2):149-57 PubMed
J Clin Microbiol. 2000 Jun;38(6):2191-9 PubMed
Expert Rev Anti Infect Ther. 2011 Jul;9(7):787-97 PubMed
Trends Microbiol. 2007 Aug;15(8):350-4 PubMed
Acta Derm Venereol. 2007;87(1):39-42 PubMed
Clin Infect Dis. 1995 Aug;21(2):380-9 PubMed
Open Neurol J. 2012;6:129-39 PubMed
FEMS Immunol Med Microbiol. 2007 Feb;49(1):13-21 PubMed
Diagn Microbiol Infect Dis. 2012 Jul;73(3):246-51 PubMed
Conn Med. 1999 Oct;63(10):589-91 PubMed
Int J Dermatol. 2008 Oct;47(10):1004-10 PubMed
APMIS. 2010 Sep 1;118(9):665-73 PubMed
Short-term stability of Borrelia garinii in cerebrospinal fluid
